company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q2,2010-04-01,2010-06-30,2012-02-10 17:01:00+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5838000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q2,2010-04-01,2010-06-30,2012-02-10 17:01:00+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5838000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q2,2010-04-01,2010-06-30,2012-02-10 17:01:00+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q2,2010-04-01,2010-06-30,2012-02-10 17:01:00+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,5838000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q2,2010-04-01,2010-06-30,2012-02-10 17:01:00+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3290000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q2,2010-04-01,2010-06-30,2012-02-10 17:01:00+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6602000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q2,2010-04-01,2010-06-30,2012-02-10 17:01:00+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-426000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q2,2010-04-01,2010-06-30,2012-02-10 17:01:00+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,0.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q2,2010-04-01,2010-06-30,2012-02-10 17:01:00+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,9466000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q2,2010-04-01,2010-06-30,2012-02-10 17:01:00+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-3628000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q2,2010-04-01,2010-06-30,2012-02-10 17:01:00+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,13000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q2,2010-04-01,2010-06-30,2012-02-10 17:01:00+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,118000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q2,2010-04-01,2010-06-30,2012-02-10 17:01:00+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,3858000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q2,2010-04-01,2010-06-30,2012-02-10 17:01:00+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,3963000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q2,2010-04-01,2010-06-30,2012-02-10 17:01:00+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,335000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q2,2010-04-01,2010-06-30,2012-02-10 17:01:00+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,625000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q2,2010-04-01,2010-06-30,2012-02-10 17:01:00+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-290000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q2,2010-04-01,2010-06-30,2012-02-10 17:01:00+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,7000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q2,2010-04-01,2010-06-30,2012-02-10 17:01:00+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-283000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q2,2010-04-01,2010-06-30,2012-02-10 17:01:00+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-283000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q2,2010-04-01,2010-06-30,2012-02-10 17:01:00+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,19608685.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q2,2010-04-01,2010-06-30,2012-02-10 17:01:00+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.01
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q2,2010-04-01,2010-06-30,2012-02-10 17:01:00+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,19608685.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q2,2010-04-01,2010-06-30,2012-02-10 17:01:00+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.01
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q2,2010-04-01,2010-06-30,2012-02-10 17:01:00+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,28300000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q2,2010-04-01,2010-06-30,2012-02-10 17:01:00+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.01
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q3,2010-07-01,2010-09-30,2012-02-10 17:02:51+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,7802000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q3,2010-07-01,2010-09-30,2012-02-10 17:02:51+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,7802000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q3,2010-07-01,2010-09-30,2012-02-10 17:02:51+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,0.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q3,2010-07-01,2010-09-30,2012-02-10 17:02:51+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,7802000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q3,2010-07-01,2010-09-30,2012-02-10 17:02:51+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3074000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q3,2010-07-01,2010-09-30,2012-02-10 17:02:51+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4935000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q3,2010-07-01,2010-09-30,2012-02-10 17:02:51+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-426000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q3,2010-07-01,2010-09-30,2012-02-10 17:02:51+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,15894000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q3,2010-07-01,2010-09-30,2012-02-10 17:02:51+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,23477000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q3,2010-07-01,2010-09-30,2012-02-10 17:02:51+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-15675000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q3,2010-07-01,2010-09-30,2012-02-10 17:02:51+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,8000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q3,2010-07-01,2010-09-30,2012-02-10 17:02:51+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,59000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q3,2010-07-01,2010-09-30,2012-02-10 17:02:51+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,4188000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q3,2010-07-01,2010-09-30,2012-02-10 17:02:51+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,4239000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q3,2010-07-01,2010-09-30,2012-02-10 17:02:51+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-11436000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q3,2010-07-01,2010-09-30,2012-02-10 17:02:51+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,419000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q3,2010-07-01,2010-09-30,2012-02-10 17:02:51+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-11855000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q3,2010-07-01,2010-09-30,2012-02-10 17:02:51+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,12000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q3,2010-07-01,2010-09-30,2012-02-10 17:02:51+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-11843000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q3,2010-07-01,2010-09-30,2012-02-10 17:02:51+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-11843000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q3,2010-07-01,2010-09-30,2012-02-10 17:02:51+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,19629693.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q3,2010-07-01,2010-09-30,2012-02-10 17:02:51+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.6
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q3,2010-07-01,2010-09-30,2012-02-10 17:02:51+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,19629693.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q3,2010-07-01,2010-09-30,2012-02-10 17:02:51+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.6
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q3,2010-07-01,2010-09-30,2012-02-10 17:02:51+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,19700000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2010.0,Q3,2010-07-01,2010-09-30,2012-02-10 17:02:51+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.6
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q1,2011-01-01,2011-03-31,2012-11-14 14:01:44+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3896000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q1,2011-01-01,2011-03-31,2012-11-14 14:01:44+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3896000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q1,2011-01-01,2011-03-31,2012-11-14 14:01:44+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,525000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q1,2011-01-01,2011-03-31,2012-11-14 14:01:44+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,525000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q1,2011-01-01,2011-03-31,2012-11-14 14:01:44+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3371000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q1,2011-01-01,2011-03-31,2012-11-14 14:01:44+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3445000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q1,2011-01-01,2011-03-31,2012-11-14 14:01:44+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1986000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q1,2011-01-01,2011-03-31,2012-11-14 14:01:44+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-426000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q1,2011-01-01,2011-03-31,2012-11-14 14:01:44+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,-151000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q1,2011-01-01,2011-03-31,2012-11-14 14:01:44+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,4854000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q1,2011-01-01,2011-03-31,2012-11-14 14:01:44+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-1483000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q1,2011-01-01,2011-03-31,2012-11-14 14:01:44+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,423000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q1,2011-01-01,2011-03-31,2012-11-14 14:01:44+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,37000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q1,2011-01-01,2011-03-31,2012-11-14 14:01:44+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2240000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q1,2011-01-01,2011-03-31,2012-11-14 14:01:44+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2626000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q1,2011-01-01,2011-03-31,2012-11-14 14:01:44+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-4109000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q1,2011-01-01,2011-03-31,2012-11-14 14:01:44+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-13730000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q1,2011-01-01,2011-03-31,2012-11-14 14:01:44+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,9621000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q1,2011-01-01,2011-03-31,2012-11-14 14:01:44+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,4000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q1,2011-01-01,2011-03-31,2012-11-14 14:01:44+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,9625000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q1,2011-01-01,2011-03-31,2012-11-14 14:01:44+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,9625000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q1,2011-01-01,2011-03-31,2012-11-14 14:01:44+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,19600000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q1,2011-01-01,2011-03-31,2012-11-14 14:01:44+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.49
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q1,2011-01-01,2011-03-31,2012-11-14 14:01:44+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,19600000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q1,2011-01-01,2011-03-31,2012-11-14 14:01:44+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.49
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q1,2011-01-01,2011-03-31,2012-11-14 14:01:44+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,19623249.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q1,2011-01-01,2011-03-31,2012-11-14 14:01:44+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.49
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q2,2011-04-01,2011-06-30,2012-11-14 14:03:28+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,7463000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q2,2011-04-01,2011-06-30,2012-11-14 14:03:28+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,7463000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q2,2011-04-01,2011-06-30,2012-11-14 14:03:28+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1623000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q2,2011-04-01,2011-06-30,2012-11-14 14:03:28+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1623000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q2,2011-04-01,2011-06-30,2012-11-14 14:03:28+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,5840000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q2,2011-04-01,2011-06-30,2012-11-14 14:03:28+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3855000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q2,2011-04-01,2011-06-30,2012-11-14 14:03:28+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3237000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q2,2011-04-01,2011-06-30,2012-11-14 14:03:28+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-426000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q2,2011-04-01,2011-06-30,2012-11-14 14:03:28+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,-16000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q2,2011-04-01,2011-06-30,2012-11-14 14:03:28+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,6650000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q2,2011-04-01,2011-06-30,2012-11-14 14:03:28+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-810000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q2,2011-04-01,2011-06-30,2012-11-14 14:03:28+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,674000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q2,2011-04-01,2011-06-30,2012-11-14 14:03:28+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1203000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q2,2011-04-01,2011-06-30,2012-11-14 14:03:28+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,529000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q2,2011-04-01,2011-06-30,2012-11-14 14:03:28+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-281000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q2,2011-04-01,2011-06-30,2012-11-14 14:03:28+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,141000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q2,2011-04-01,2011-06-30,2012-11-14 14:03:28+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-422000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q2,2011-04-01,2011-06-30,2012-11-14 14:03:28+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-422000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q2,2011-04-01,2011-06-30,2012-11-14 14:03:28+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-422000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q2,2011-04-01,2011-06-30,2012-11-14 14:03:28+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,19650260.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q2,2011-04-01,2011-06-30,2012-11-14 14:03:28+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.02
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q2,2011-04-01,2011-06-30,2012-11-14 14:03:28+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,19650260.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q2,2011-04-01,2011-06-30,2012-11-14 14:03:28+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.02
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q2,2011-04-01,2011-06-30,2012-11-14 14:03:28+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,21100000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q2,2011-04-01,2011-06-30,2012-11-14 14:03:28+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.02
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q3,2011-07-01,2011-09-30,2012-11-14 14:05:56+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5741000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q3,2011-07-01,2011-09-30,2012-11-14 14:05:56+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5741000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q3,2011-07-01,2011-09-30,2012-11-14 14:05:56+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,703000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q3,2011-07-01,2011-09-30,2012-11-14 14:05:56+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,703000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q3,2011-07-01,2011-09-30,2012-11-14 14:05:56+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,5038000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q3,2011-07-01,2011-09-30,2012-11-14 14:05:56+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3962000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q3,2011-07-01,2011-09-30,2012-11-14 14:05:56+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4753000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q3,2011-07-01,2011-09-30,2012-11-14 14:05:56+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-426000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q3,2011-07-01,2011-09-30,2012-11-14 14:05:56+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,-2000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q3,2011-07-01,2011-09-30,2012-11-14 14:05:56+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,8287000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q3,2011-07-01,2011-09-30,2012-11-14 14:05:56+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-3249000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q3,2011-07-01,2011-09-30,2012-11-14 14:05:56+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,699000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q3,2011-07-01,2011-09-30,2012-11-14 14:05:56+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-208000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q3,2011-07-01,2011-09-30,2012-11-14 14:05:56+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-907000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q3,2011-07-01,2011-09-30,2012-11-14 14:05:56+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-4156000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q3,2011-07-01,2011-09-30,2012-11-14 14:05:56+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,22000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q3,2011-07-01,2011-09-30,2012-11-14 14:05:56+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-4178000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q3,2011-07-01,2011-09-30,2012-11-14 14:05:56+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,0.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q3,2011-07-01,2011-09-30,2012-11-14 14:05:56+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-4178000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q3,2011-07-01,2011-09-30,2012-11-14 14:05:56+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-4178000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q3,2011-07-01,2011-09-30,2012-11-14 14:05:56+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,19673160.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q3,2011-07-01,2011-09-30,2012-11-14 14:05:56+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.21
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q3,2011-07-01,2011-09-30,2012-11-14 14:05:56+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,19673160.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q3,2011-07-01,2011-09-30,2012-11-14 14:05:56+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.21
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q3,2011-07-01,2011-09-30,2012-11-14 14:05:56+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,19900000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q3,2011-07-01,2011-09-30,2012-11-14 14:05:56+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.21
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q4,2011-10-01,2011-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,12937000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q4,2011-10-01,2011-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,12937000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q4,2011-10-01,2011-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2058000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q4,2011-10-01,2011-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2058000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,10879000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3321000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2597000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-424000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,721000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,6215000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,4664000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,501000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-37000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,862000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,324000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,4988000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,297000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q4,2011-10-01,2011-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,4691000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q4,2011-10-01,2011-12-31,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-1000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q4,2011-10-01,2011-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,4690000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q4,2011-10-01,2011-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,4690000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q4,2011-10-01,2011-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,19655632.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q4,2011-10-01,2011-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.24
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q4,2011-10-01,2011-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,19713320.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q4,2011-10-01,2011-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.24
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q4,2011-10-01,2011-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,19800000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2011.0,Q4,2011-10-01,2011-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.24
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:09:09+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5636000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:09:09+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5636000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:09:09+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,155000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:09:09+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,155000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:09:09+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,5481000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:09:09+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3416000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:09:09+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2817000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:09:09+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,87000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:09:09+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,6320000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:09:09+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-839000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:09:09+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,701000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:09:09+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,767000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:09:09+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,66000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:09:09+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-773000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:09:09+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-35000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:09:09+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-738000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:09:09+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,1871000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:09:09+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1133000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:09:09+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1133000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:09:09+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,19709078.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:09:09+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.06
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:09:09+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,19738801.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:09:09+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.06
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:09:09+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,18900000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:09:09+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.06
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 10:23:35+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5742000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 10:23:35+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5742000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 10:23:35+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,435000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 10:23:35+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,435000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 10:23:35+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,5307000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 10:23:35+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3858000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 10:23:35+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2850000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 10:23:35+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,414000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 10:23:35+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,7122000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 10:23:35+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-1815000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 10:23:35+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,762000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 10:23:35+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1413000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 10:23:35+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2175000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 10:23:35+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-3990000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 10:23:35+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,338000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 10:23:35+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-4328000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 10:23:35+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,1799000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 10:23:35+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-2529000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 10:23:35+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-2529000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 10:23:35+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,19749266.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 10:23:35+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.13
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 10:23:35+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,19749266.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 10:23:35+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.13
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 10:23:35+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,19500000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q2,2012-04-01,2012-06-30,2013-08-01 10:23:35+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.13
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 17:28:23+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6375000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 17:28:23+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6375000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 17:28:23+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,683000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 17:28:23+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,683000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 17:28:23+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,5692000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 17:28:23+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4306000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 17:28:23+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2647000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 17:28:23+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,164000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 17:28:23+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,7117000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 17:28:23+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-1425000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 17:28:23+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,735000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 17:28:23+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,2108000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 17:28:23+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1373000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 17:28:23+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-52000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 17:28:23+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,142000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 17:28:23+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-194000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 17:28:23+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,0.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 17:28:23+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-194000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 17:28:23+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-194000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 17:28:23+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,19917676.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 17:28:23+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.01
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 17:28:23+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,19917676.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 17:28:23+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.01
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 17:28:23+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,19400000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q3,2012-07-01,2012-09-30,2013-11-08 17:28:23+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.01
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q4,2012-10-01,2012-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,13635000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q4,2012-10-01,2012-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,13635000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q4,2012-10-01,2012-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2328000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q4,2012-10-01,2012-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2328000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,11307000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4202000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2476000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,357000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q4,2012-10-01,2012-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,7035000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,4272000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,726000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q4,2012-10-01,2012-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2596000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q4,2012-10-01,2012-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3322000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,950000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q4,2012-10-01,2012-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-1636000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q4,2012-10-01,2012-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2586000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q4,2012-10-01,2012-12-31,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-1523000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q4,2012-10-01,2012-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1063000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q4,2012-10-01,2012-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1063000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q4,2012-10-01,2012-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,19853095.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q4,2012-10-01,2012-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.05
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q4,2012-10-01,2012-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,19853095.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q4,2012-10-01,2012-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.05
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q4,2012-10-01,2012-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,17600000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2012.0,Q4,2012-10-01,2012-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.05
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 17:30:39+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,11651000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 17:30:39+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,11651000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 17:30:39+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,663000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 17:30:39+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,663000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 17:30:39+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,10988000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 17:30:39+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4502000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 17:30:39+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2465000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 17:30:39+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,89000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 17:30:39+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,7056000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 17:30:39+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,3932000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 17:30:39+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,912000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 17:30:39+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1650000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 17:30:39+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2562000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 17:30:39+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1370000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 17:30:39+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,66000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 17:30:39+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1304000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 17:30:39+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,191000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 17:30:39+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1495000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 17:30:39+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1495000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 17:30:39+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,20189378.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 17:30:39+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.07
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 17:30:39+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,20280030.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 17:30:39+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.07
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 17:30:39+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,21400000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q1,2013-01-01,2013-03-31,2014-05-07 17:30:39+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.07
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q2,2013-04-01,2013-06-30,2014-08-05 17:22:02+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,9580000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q2,2013-04-01,2013-06-30,2014-08-05 17:22:02+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,9580000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q2,2013-04-01,2013-06-30,2014-08-05 17:22:02+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1214000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q2,2013-04-01,2013-06-30,2014-08-05 17:22:02+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1214000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q2,2013-04-01,2013-06-30,2014-08-05 17:22:02+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8366000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q2,2013-04-01,2013-06-30,2014-08-05 17:22:02+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4306000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q2,2013-04-01,2013-06-30,2014-08-05 17:22:02+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2502000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q2,2013-04-01,2013-06-30,2014-08-05 17:22:02+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,44000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q2,2013-04-01,2013-06-30,2014-08-05 17:22:02+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,6852000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q2,2013-04-01,2013-06-30,2014-08-05 17:22:02+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1514000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q2,2013-04-01,2013-06-30,2014-08-05 17:22:02+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,453000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q2,2013-04-01,2013-06-30,2014-08-05 17:22:02+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,2743000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q2,2013-04-01,2013-06-30,2014-08-05 17:22:02+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,2290000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q2,2013-04-01,2013-06-30,2014-08-05 17:22:02+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3804000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q2,2013-04-01,2013-06-30,2014-08-05 17:22:02+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,110000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q2,2013-04-01,2013-06-30,2014-08-05 17:22:02+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,3694000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q2,2013-04-01,2013-06-30,2014-08-05 17:22:02+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,2397000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q2,2013-04-01,2013-06-30,2014-08-05 17:22:02+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,6091000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q2,2013-04-01,2013-06-30,2014-08-05 17:22:02+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q2,2013-04-01,2013-06-30,2014-08-05 17:22:02+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,6091000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q2,2013-04-01,2013-06-30,2014-08-05 17:22:02+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,20258618.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q2,2013-04-01,2013-06-30,2014-08-05 17:22:02+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.3
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q2,2013-04-01,2013-06-30,2014-08-05 17:22:02+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,20427360.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q2,2013-04-01,2013-06-30,2014-08-05 17:22:02+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.3
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q2,2013-04-01,2013-06-30,2014-08-05 17:22:02+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,20300000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q2,2013-04-01,2013-06-30,2014-08-05 17:22:02+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.3
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q3,2013-07-01,2013-09-30,2014-10-31 16:23:44+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,13005000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q3,2013-07-01,2013-09-30,2014-10-31 16:23:44+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,13005000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q3,2013-07-01,2013-09-30,2014-10-31 16:23:44+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2538000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q3,2013-07-01,2013-09-30,2014-10-31 16:23:44+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2538000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q3,2013-07-01,2013-09-30,2014-10-31 16:23:44+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,10467000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q3,2013-07-01,2013-09-30,2014-10-31 16:23:44+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4756000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q3,2013-07-01,2013-09-30,2014-10-31 16:23:44+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2414000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q3,2013-07-01,2013-09-30,2014-10-31 16:23:44+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,227000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q3,2013-07-01,2013-09-30,2014-10-31 16:23:44+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,7397000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q3,2013-07-01,2013-09-30,2014-10-31 16:23:44+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,3070000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q3,2013-07-01,2013-09-30,2014-10-31 16:23:44+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,394000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q3,2013-07-01,2013-09-30,2014-10-31 16:23:44+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-651000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q3,2013-07-01,2013-09-30,2014-10-31 16:23:44+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1045000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q3,2013-07-01,2013-09-30,2014-10-31 16:23:44+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,2025000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q3,2013-07-01,2013-09-30,2014-10-31 16:23:44+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,60000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q3,2013-07-01,2013-09-30,2014-10-31 16:23:44+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1965000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q3,2013-07-01,2013-09-30,2014-10-31 16:23:44+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,0.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q3,2013-07-01,2013-09-30,2014-10-31 16:23:44+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1965000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q3,2013-07-01,2013-09-30,2014-10-31 16:23:44+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q3,2013-07-01,2013-09-30,2014-10-31 16:23:44+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1965000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q3,2013-07-01,2013-09-30,2014-10-31 16:23:44+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,20357558.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q3,2013-07-01,2013-09-30,2014-10-31 16:23:44+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.1
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q3,2013-07-01,2013-09-30,2014-10-31 16:23:44+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,20843742.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q3,2013-07-01,2013-09-30,2014-10-31 16:23:44+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.09
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q3,2013-07-01,2013-09-30,2014-10-31 16:23:44+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,19700000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q3,2013-07-01,2013-09-30,2014-10-31 16:23:44+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.1
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q4,2013-10-01,2013-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,14737000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,14737000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q4,2013-10-01,2013-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1317000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1317000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,13420000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4420000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2373000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,200000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,6993000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,6427000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,318000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-4102000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4420000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,2007000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,138000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q4,2013-10-01,2013-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1869000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q4,2013-10-01,2013-12-31,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-2588000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q4,2013-10-01,2013-12-31,,netincome,otheradjustmentstoconsolidatednetincome,Other Adjustments to Consolidated Net Income / (Loss),+,credit,usd,2588000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q4,2013-10-01,2013-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1869000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q4,2013-10-01,2013-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1869000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q4,2013-10-01,2013-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,20312395.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q4,2013-10-01,2013-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.09
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q4,2013-10-01,2013-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,20745454.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q4,2013-10-01,2013-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.09
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q4,2013-10-01,2013-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,20400000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2013.0,Q4,2013-10-01,2013-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.09
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 08:38:24+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,15958000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 08:38:24+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,15958000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 08:38:24+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2451000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 08:38:24+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2451000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 08:38:24+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,13507000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 08:38:24+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5072000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 08:38:24+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3131000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 08:38:24+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,204000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 08:38:24+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,8407000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 08:38:24+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,5100000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 08:38:24+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,248000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 08:38:24+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2702000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 08:38:24+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2950000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 08:38:24+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,2150000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 08:38:24+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,53000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 08:38:24+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,2097000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 08:38:24+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,2097000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 08:38:24+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 08:38:24+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,2097000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 08:38:24+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,20600683.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 08:38:24+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.1
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 08:38:24+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,21208023.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 08:38:24+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.1
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 08:38:24+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,21000000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q1,2014-01-01,2014-03-31,2015-05-11 08:38:24+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.1
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 20:37:46+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,10608000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 20:37:46+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,10608000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 20:37:46+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1186000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 20:37:46+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1186000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 20:37:46+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,9422000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 20:37:46+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5239000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 20:37:46+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2689000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 20:37:46+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,136000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 20:37:46+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,8064000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 20:37:46+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1358000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 20:37:46+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,181000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 20:37:46+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,0.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 20:37:46+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,64000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 20:37:46+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-117000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 20:37:46+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1241000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 20:37:46+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-47000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 20:37:46+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1288000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 20:37:46+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1288000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 20:37:46+00:00,netincometocommon,otheradjustmentstonetincometocommon,Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders),-,debit,usd,-304000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 20:37:46+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1592000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 20:37:46+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,20738299.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 20:37:46+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.08
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 20:37:46+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,21780034.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 20:37:46+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.07
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 20:37:46+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,19900000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q2,2014-04-01,2014-06-30,2015-08-04 20:37:46+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.08
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:26:11+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,14973000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:26:11+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,14973000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:26:11+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1496000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:26:11+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1496000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:26:11+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,13477000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:26:11+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6742000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:26:11+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3021000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:26:11+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,182000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:26:11+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,9945000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:26:11+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,3532000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:26:11+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1516000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:26:11+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,0.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:26:11+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1115000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:26:11+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2631000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:26:11+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,901000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:26:11+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,124000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:26:11+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,777000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:26:11+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,777000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:26:11+00:00,netincometocommon,otheradjustmentstonetincometocommon,Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders),-,debit,usd,-503000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:26:11+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1280000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:26:11+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,20417187.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:26:11+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.06
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:26:11+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,21345311.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:26:11+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.06
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:26:11+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,21300000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q3,2014-07-01,2014-09-30,2015-11-09 17:26:11+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.06
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q4,2014-10-01,2014-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,22999000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,22999000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q4,2014-10-01,2014-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4003000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4003000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,18996000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5517000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,906000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,2375000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,562000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,9360000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,9636000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2915000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,289000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2626000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,7010000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,280000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q4,2014-10-01,2014-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,6730000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q4,2014-10-01,2014-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,6730000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q4,2014-10-01,2014-12-31,,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-1132000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q4,2014-10-01,2014-12-31,,netincometocommon,otheradjustmentstonetincometocommon,Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders),-,debit,usd,807000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q4,2014-10-01,2014-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,7055000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q4,2014-10-01,2014-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,20419000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q4,2014-10-01,2014-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.35
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q4,2014-10-01,2014-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,21433000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q4,2014-10-01,2014-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.33
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q4,2014-10-01,2014-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,20400000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2014.0,Q4,2014-10-01,2014-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.35
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q1,2015-01-01,2015-03-31,2016-11-14 18:10:40+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,14602000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q1,2015-01-01,2015-03-31,2016-11-14 18:10:40+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,14602000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q1,2015-01-01,2015-03-31,2016-11-14 18:10:40+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1074000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q1,2015-01-01,2015-03-31,2016-11-14 18:10:40+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1074000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q1,2015-01-01,2015-03-31,2016-11-14 18:10:40+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,13528000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q1,2015-01-01,2015-03-31,2016-11-14 18:10:40+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5994000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q1,2015-01-01,2015-03-31,2016-11-14 18:10:40+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3368000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q1,2015-01-01,2015-03-31,2016-11-14 18:10:40+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,594000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q1,2015-01-01,2015-03-31,2016-11-14 18:10:40+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,223000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q1,2015-01-01,2015-03-31,2016-11-14 18:10:40+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,10179000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q1,2015-01-01,2015-03-31,2016-11-14 18:10:40+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,3349000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q1,2015-01-01,2015-03-31,2016-11-14 18:10:40+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2973000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q1,2015-01-01,2015-03-31,2016-11-14 18:10:40+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,0.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q1,2015-01-01,2015-03-31,2016-11-14 18:10:40+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-450000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q1,2015-01-01,2015-03-31,2016-11-14 18:10:40+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3423000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q1,2015-01-01,2015-03-31,2016-11-14 18:10:40+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-74000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q1,2015-01-01,2015-03-31,2016-11-14 18:10:40+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,15000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q1,2015-01-01,2015-03-31,2016-11-14 18:10:40+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-89000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q1,2015-01-01,2015-03-31,2016-11-14 18:10:40+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,0.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q1,2015-01-01,2015-03-31,2016-11-14 18:10:40+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-89000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q1,2015-01-01,2015-03-31,2016-11-14 18:10:40+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-843000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q1,2015-01-01,2015-03-31,2016-11-14 18:10:40+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,754000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q1,2015-01-01,2015-03-31,2016-11-14 18:10:40+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,19612000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q1,2015-01-01,2015-03-31,2016-11-14 18:10:40+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.04
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q1,2015-01-01,2015-03-31,2016-11-14 18:10:40+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,20630788.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q1,2015-01-01,2015-03-31,2016-11-14 18:10:40+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.04
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q1,2015-01-01,2015-03-31,2016-11-14 18:10:40+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,18900000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q1,2015-01-01,2015-03-31,2016-11-14 18:10:40+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.04
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q2,2015-04-01,2015-06-30,2016-11-14 18:26:07+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,18418000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q2,2015-04-01,2015-06-30,2016-11-14 18:26:07+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,18418000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q2,2015-04-01,2015-06-30,2016-11-14 18:26:07+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2600000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q2,2015-04-01,2015-06-30,2016-11-14 18:26:07+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2600000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q2,2015-04-01,2015-06-30,2016-11-14 18:26:07+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,15818000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q2,2015-04-01,2015-06-30,2016-11-14 18:26:07+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7225000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q2,2015-04-01,2015-06-30,2016-11-14 18:26:07+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3416000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q2,2015-04-01,2015-06-30,2016-11-14 18:26:07+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,594000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q2,2015-04-01,2015-06-30,2016-11-14 18:26:07+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,218000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q2,2015-04-01,2015-06-30,2016-11-14 18:26:07+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11453000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q2,2015-04-01,2015-06-30,2016-11-14 18:26:07+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,4365000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q2,2015-04-01,2015-06-30,2016-11-14 18:26:07+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2969000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q2,2015-04-01,2015-06-30,2016-11-14 18:26:07+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,27320000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q2,2015-04-01,2015-06-30,2016-11-14 18:26:07+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-6424000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q2,2015-04-01,2015-06-30,2016-11-14 18:26:07+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,17927000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q2,2015-04-01,2015-06-30,2016-11-14 18:26:07+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,22292000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q2,2015-04-01,2015-06-30,2016-11-14 18:26:07+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,265000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q2,2015-04-01,2015-06-30,2016-11-14 18:26:07+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,22027000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q2,2015-04-01,2015-06-30,2016-11-14 18:26:07+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,0.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q2,2015-04-01,2015-06-30,2016-11-14 18:26:07+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,22027000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q2,2015-04-01,2015-06-30,2016-11-14 18:26:07+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,-1537000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q2,2015-04-01,2015-06-30,2016-11-14 18:26:07+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,23564000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q2,2015-04-01,2015-06-30,2016-11-14 18:26:07+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,19725000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q2,2015-04-01,2015-06-30,2016-11-14 18:26:07+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,1.19
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q2,2015-04-01,2015-06-30,2016-11-14 18:26:07+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,21276404.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q2,2015-04-01,2015-06-30,2016-11-14 18:26:07+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.11
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q2,2015-04-01,2015-06-30,2016-11-14 18:26:07+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,19800000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q2,2015-04-01,2015-06-30,2016-11-14 18:26:07+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,1.19
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q3,2015-07-01,2015-09-30,2016-11-14 19:12:35+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,17701000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q3,2015-07-01,2015-09-30,2016-11-14 19:12:35+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,17701000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q3,2015-07-01,2015-09-30,2016-11-14 19:12:35+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1250000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q3,2015-07-01,2015-09-30,2016-11-14 19:12:35+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1250000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q3,2015-07-01,2015-09-30,2016-11-14 19:12:35+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,16451000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q3,2015-07-01,2015-09-30,2016-11-14 19:12:35+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4971000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q3,2015-07-01,2015-09-30,2016-11-14 19:12:35+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,1945000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q3,2015-07-01,2015-09-30,2016-11-14 19:12:35+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,593000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q3,2015-07-01,2015-09-30,2016-11-14 19:12:35+00:00,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,345000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q3,2015-07-01,2015-09-30,2016-11-14 19:12:35+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,7854000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q3,2015-07-01,2015-09-30,2016-11-14 19:12:35+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,8597000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q3,2015-07-01,2015-09-30,2016-11-14 19:12:35+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2930000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q3,2015-07-01,2015-09-30,2016-11-14 19:12:35+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-2169000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q3,2015-07-01,2015-09-30,2016-11-14 19:12:35+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,3786000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q3,2015-07-01,2015-09-30,2016-11-14 19:12:35+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1313000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q3,2015-07-01,2015-09-30,2016-11-14 19:12:35+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,7284000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q3,2015-07-01,2015-09-30,2016-11-14 19:12:35+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-191881000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q3,2015-07-01,2015-09-30,2016-11-14 19:12:35+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,199165000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q3,2015-07-01,2015-09-30,2016-11-14 19:12:35+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,0.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q3,2015-07-01,2015-09-30,2016-11-14 19:12:35+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,199165000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q3,2015-07-01,2015-09-30,2016-11-14 19:12:35+00:00,netincometocommon,netincometononcontrollinginterest,Net Income / (Loss) Attributable to Noncontrolling Interest,-,debit,usd,0.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q3,2015-07-01,2015-09-30,2016-11-14 19:12:35+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,199165000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q3,2015-07-01,2015-09-30,2016-11-14 19:12:35+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,19887000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q3,2015-07-01,2015-09-30,2016-11-14 19:12:35+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,10.01
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q3,2015-07-01,2015-09-30,2016-11-14 19:12:35+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,21459648.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q3,2015-07-01,2015-09-30,2016-11-14 19:12:35+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,9.28
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q3,2015-07-01,2015-09-30,2016-11-14 19:12:35+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,19900000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q3,2015-07-01,2015-09-30,2016-11-14 19:12:35+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,10.01
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q4,2015-10-01,2015-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,21193000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,21193000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q4,2015-10-01,2015-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,883000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,883000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,20310000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7208000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,2276000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,594000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,restructuringcharge,Restructuring Charge,+,debit,usd,-786000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,9292000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,11018000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2930000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-2104000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-157000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-5191000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,5827000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-514000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q4,2015-10-01,2015-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,6341000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,6341000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q4,2015-10-01,2015-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,6341000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q4,2015-10-01,2015-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,19790000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q4,2015-10-01,2015-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.37
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q4,2015-10-01,2015-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,21228000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q4,2015-10-01,2015-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.4
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q4,2015-10-01,2015-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,19800000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2015.0,Q4,2015-10-01,2015-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.37
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:23:04+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,29648000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:23:04+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,29648000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:23:04+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,955000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:23:04+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,955000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:23:04+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,28693000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:23:04+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7069000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:23:04+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4004000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:23:04+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,2524000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:23:04+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13597000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:23:04+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,15096000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:23:04+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3005000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:23:04+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-1605000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:23:04+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-915000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:23:04+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-5525000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:23:04+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,9571000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:23:04+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,3694000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:23:04+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,5877000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:23:04+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,731000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:23:04+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,6608000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:23:04+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,6608000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:23:04+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,20708000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:23:04+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.32
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:23:04+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,22283979.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:23:04+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.3
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:23:04+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,20700000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:23:04+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.32
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:36:02+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,19521000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:36:02+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,19521000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:36:02+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,720000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:36:02+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,720000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:36:02+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,18801000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:36:02+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7237000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:36:02+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4914000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:36:02+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,2681000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:36:02+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,14832000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:36:02+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,3969000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:36:02+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3051000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:36:02+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-11138000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:36:02+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,169000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:36:02+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-14020000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:36:02+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-10051000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:36:02+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-3881000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:36:02+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-6170000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:36:02+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,0.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:36:02+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-6170000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:36:02+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-6170000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:36:02+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,20832000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:36:02+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.3
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:36:02+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,20832000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:36:02+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.3
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:36:02+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,20600000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q2,2016-04-01,2016-06-30,2017-08-08 17:36:02+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.3
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:08:48+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,21619000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:08:48+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,21619000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:08:48+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,999000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:08:48+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,999000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:08:48+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,20620000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:08:48+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6550000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:08:48+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5898000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:08:48+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,2706000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:08:48+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,15154000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:08:48+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,5466000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:08:48+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3116000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:08:48+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-1396000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:08:48+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,257000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:08:48+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4255000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:08:48+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1211000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:08:48+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,160000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:08:48+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,1051000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:08:48+00:00,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,0.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:08:48+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,1051000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:08:48+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,1051000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:08:48+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,20887000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:08:48+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.05
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:08:48+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,22997000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:08:48+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.05
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:08:48+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,21000000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q3,2016-07-01,2016-09-30,2017-11-09 16:08:48+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.05
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q4,2016-10-01,2016-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,38185000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,38185000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q4,2016-10-01,2016-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2897000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2897000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,35288000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6797000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6405000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,2732000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,15934000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,19354000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3670000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,14803000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-23258000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-12125000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,7229000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,10354000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q4,2016-10-01,2016-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-3125000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q4,2016-10-01,2016-12-31,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,-731000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q4,2016-10-01,2016-12-31,,netincome,otheradjustmentstoconsolidatednetincome,Other Adjustments to Consolidated Net Income / (Loss),+,credit,usd,731000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-3125000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q4,2016-10-01,2016-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-3125000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q4,2016-10-01,2016-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,20831000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q4,2016-10-01,2016-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.15
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q4,2016-10-01,2016-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,20831000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q4,2016-10-01,2016-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.13
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q4,2016-10-01,2016-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,20500000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2016.0,Q4,2016-10-01,2016-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.15
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:08:22+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,29267000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:08:22+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,29267000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:08:22+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,341000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:08:22+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,341000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:08:22+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,28926000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:08:22+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7322000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:08:22+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8673000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:08:22+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,2715000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:08:22+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,18710000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:08:22+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,10216000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:08:22+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2941000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:08:22+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-1083000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:08:22+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:08:22+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4023000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:08:22+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,6193000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:08:22+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1114000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:08:22+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,5079000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:08:22+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,5079000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:08:22+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,5079000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:08:22+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,20938000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:08:22+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.24
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:08:22+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,23019189.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:08:22+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.22
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:08:22+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,21200000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:08:22+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.24
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 17:17:11+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,27995000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 17:17:11+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,27995000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 17:17:11+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,903000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 17:17:11+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,903000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 17:17:11+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,27092000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 17:17:11+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6549000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 17:17:11+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4822000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 17:17:11+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,2706000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 17:17:11+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,14077000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 17:17:11+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,13015000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 17:17:11+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3341000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 17:17:11+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-919000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 17:17:11+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-455000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 17:17:11+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4715000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 17:17:11+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,8300000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 17:17:11+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,2242000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 17:17:11+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,6058000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 17:17:11+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,6058000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 17:17:11+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,6058000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 17:17:11+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,21013000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 17:17:11+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.29
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 17:17:11+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,23215900.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 17:17:11+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.26
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 17:17:11+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,20900000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q2,2017-04-01,2017-06-30,2018-08-08 17:17:11+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.29
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:04:39+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,33375000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:04:39+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,33375000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:04:39+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2385000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:04:39+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2385000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:04:39+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,30990000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:04:39+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7032000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:04:39+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4759000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:04:39+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,2706000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:04:39+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,14497000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:04:39+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,16493000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:04:39+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3386000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:04:39+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-455000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:04:39+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-581000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:04:39+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-4422000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:04:39+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,12071000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:04:39+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,3645000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:04:39+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,8426000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:04:39+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,8426000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:04:39+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,8426000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:04:39+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,21071000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:04:39+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.4
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:04:39+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,23551245.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:04:39+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.36
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:04:39+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,21100000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 16:04:39+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.4
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:23+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,56157000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:23+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,56157000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:23+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,788000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:23+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,788000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:23+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,55369000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:23+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7643000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:23+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7407000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:23+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,3278000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:23+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:23+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,18328000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:23+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,37041000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:23+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,3480000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:23+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,21972000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:23+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-221000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:23+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,18271000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:23+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,55312000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:23+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,10033000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:23+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,45279000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:23+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,45279000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:23+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,45279000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:23+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,21209000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:23+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,2.13
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:23+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,24800000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:23+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,1.83
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:23+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,21300000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:23+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,2.13
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:12:53+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,90043000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:12:53+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,90043000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:12:53+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1134000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:12:53+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1134000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:12:53+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,88909000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:12:53+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,9294000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:12:53+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6135000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:12:53+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,3305000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:12:53+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:12:53+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,18734000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:12:53+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,70175000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:12:53+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,13454000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:12:53+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,42725000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:12:53+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-3867000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:12:53+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,25404000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:12:53+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,95579000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:12:53+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,22419000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:12:53+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,73160000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:12:53+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,73160000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:12:53+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,73160000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:12:53+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,21212000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:12:53+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,3.45
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:12:53+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,24438000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:12:53+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,2.99
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:12:53+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,21200000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q2,2018-04-01,2018-06-30,2019-08-08 16:12:53+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,3.45
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 16:05:45+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,45663000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 16:05:45+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,45663000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 16:05:45+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1460000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 16:05:45+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1460000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 16:05:45+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,44203000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 16:05:45+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,9633000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 16:05:45+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5483000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 16:05:45+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,5725000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 16:05:45+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 16:05:45+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,20841000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 16:05:45+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,23362000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 16:05:45+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,11200000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 16:05:45+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,67872000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 16:05:45+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-808000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 16:05:45+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,55864000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 16:05:45+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,79226000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 16:05:45+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,11864000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 16:05:45+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,67362000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 16:05:45+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,67362000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 16:05:45+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,67362000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 16:05:45+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,21148000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 16:05:45+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,3.19
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 16:05:45+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,24052000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 16:05:45+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,2.8
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 16:05:45+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,21100000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2018.0,Q3,2018-07-01,2018-09-30,2019-11-08 16:05:45+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,3.19
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 16:28:04+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,43484000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 16:28:04+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,43484000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 16:28:04+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,43484000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 16:28:04+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,11088000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 16:28:04+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11289000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 16:28:04+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,3503000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 16:28:04+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,3858000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 16:28:04+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,-812797000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 16:28:04+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,-783059000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 16:28:04+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,826543000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 16:28:04+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,8906000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 16:28:04+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,23202000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 16:28:04+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1874000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 16:28:04+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,16170000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 16:28:04+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,842713000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 16:28:04+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,176376000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 16:28:04+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,666337000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 16:28:04+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,666337000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 16:28:04+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,666337000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 16:28:04+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,20447000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 16:28:04+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,32.59
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 16:28:04+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,21277000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 16:28:04+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,31.32
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 16:28:04+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,20400000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q1,2019-01-01,2019-03-31,2020-05-08 16:28:04+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,32.59
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:12:53+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,24987000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:12:53+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,24987000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:12:53+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,2405000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:12:53+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,2405000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:12:53+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,22582000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:12:53+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,10994000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:12:53+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12213000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:12:53+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,3505000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:12:53+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:12:53+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,26712000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:12:53+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-4130000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:12:53+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,9012000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:12:53+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-3080000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:12:53+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1806000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:12:53+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-13898000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:12:53+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-18028000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:12:53+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-3609000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:12:53+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-14419000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:12:53+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-14419000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:12:53+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-14419000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:12:53+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,19558000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:12:53+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.74
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:12:53+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,19558000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:12:53+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.74
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:12:53+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,19500000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q2,2019-04-01,2019-06-30,2019-08-08 16:12:53+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.74
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 16:05:45+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,24808000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 16:05:45+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,24808000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 16:05:45+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3147000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 16:05:45+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3147000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 16:05:45+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,21661000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 16:05:45+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,9525000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 16:05:45+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,13742000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 16:05:45+00:00,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,3552000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 16:05:45+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,0.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 16:05:45+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,26819000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 16:05:45+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-5158000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 16:05:45+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,8993000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 16:05:45+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-3124000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 16:05:45+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2596000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 16:05:45+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-14713000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 16:05:45+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-19871000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 16:05:45+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-4620000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 16:05:45+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-15251000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 16:05:45+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-15251000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 16:05:45+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-15251000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 16:05:45+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,18770000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 16:05:45+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.81
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 16:05:45+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,18770000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 16:05:45+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.81
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 16:05:45+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,18800000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q3,2019-07-01,2019-09-30,2019-11-08 16:05:45+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.81
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q4,2019-10-01,2019-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,27003000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,27003000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q4,2019-10-01,2019-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,-5552000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,-5552000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,32555000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,10277000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,18664000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,amortizationexpense,Amortization Expense,+,debit,usd,6304000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,7489000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,42734000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-10179000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,8834000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,14320000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-3482000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,2004000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-8175000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-810000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q4,2019-10-01,2019-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-7365000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q4,2019-10-01,2019-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-7365000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q4,2019-10-01,2019-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-7365000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q4,2019-10-01,2019-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,18995000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q4,2019-10-01,2019-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,2.09
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q4,2019-10-01,2019-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,19757000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q4,2019-10-01,2019-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,2.08
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q4,2019-10-01,2019-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,19000000.0
Ligand Pharmaceuticals Inc,LGND,5493008K7TB0IKP37H79,0000886163,2019.0,Q4,2019-10-01,2019-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,2.09
